Long-term response rates of successful hepatitis B vaccination in HIV-infected patients

Vaccine

Volumn 31, Issue 7, 2013, Pages 1040-1044

  Lopes, Vania Baptista ^a   Hassing, Robert J ^a   De Vries Sluijs, Theodora E M S ^a   El Barzouhi, Abdel ^a   Hansen, Bettina E ^a   Schutten, Martin ^a   De Man, Robert A ^a   Van Der Ende, Marchina E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti HBs; Hepatitis B; Human immunodeficiency virus (HIV); Long term efficacy; Vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B ANTIBODY; VIRUS RNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD;

ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84872607411     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.047     Document Type: Article

References (16)

1. McMahon B.J., Dentiger C.M., Bruden D., Zanis C., Peters H., Hurlburt D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. Infect Dis 2009, 200(November (9)):1390-1396.
2. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Longterm efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23(July (32)):4158-4166.
3. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004, 22(January (5-6)):607-610.
4. Rey D., Krantz V., Partisani M., Schmitt M., Meyer P., Libbrecht E., et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18(January (13)):1161-1165.
5. Cruciani M., Mengoli C., Serpelloni G., Lanza A., Gomma M., Nardi S., et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009, 27(January (1)):17-22.
6. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46(April (8)):1310-1314.
7. De Vries-Sluijs T.E.M.S., Hansen B.E., Van Doornum G.J.J., Kauffmann R.H., Leyten E.M.S., Mudrikova T., et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011, 203(April (7)):984-991.
8. Van Herck K., Van Damme P., Thoelen S., Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine 1998, 16(December (20)):1933-1935.
9. Lao-Araya M., Puthanakit T., Aurpibul L., Taecharoenkul S., Sirisanthana T., Sirisanthana V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 2011, 29(May (23)):3977-3981.
10. Psevdos G., Kim J.H., Groce V., Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010, 24(July (7)):403-407.
11. Flynn P.M., Cunningham C.K., Rudy B., Wilson C.M., Kapogiannis B., Worrell C., et al. Adolescent medicine trials network for HIV/AIDS interventions (ATN). Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr 2011, 56(April (4)):325-332. PubMed PMID: 21350366.
12. Fonseca M.O., Pang L.W., De Paula Cavalheiro N., Barone A.A., Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23(April (22)):2902-2908.
13. Landrum M.L., Hullsiek K.H., Ganesan A., Weintrob A.C., Crum-Cianflone N.F., Barthel R.V., et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010, 24(February (4)):545-555.
14. Landrum M.L., Hullsiek K.H., Chun H.M., Crum-Cianflone N.F., Ganesan A., Weintrob A.C., et al. The timing of hepatitis B virus (HBV)immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol 2011, 173(January (1)):84-93.
15. Abzug M.J., Warshaw M., Rosenblatt H.M., Levin M.J., Nachman S.A., Pelton S.I., et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009, 200(September (6)):935-946.
16. Guihot A., Bourgarit A., Carcelain G., Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011, 32(March (3)):131-137.